Where the CEO of ADC Therapeutics sees ‘huge potential’ in the tech beyond oncology

The “magic bullet” approach of ADCs has been a breakthrough in cancer care — but this excitement could be just the beginning.

By Meagan Parrish • Oct. 12, 2022

Citius Pharmaceuticals sees golden opportunities in late-stage specialty assets

CEO Leonard Mazur explains how the company’s hoping to unlock the potential of its varied pipeline.

By Karissa Waddick • Oct. 11, 2022

Explore the Trendline➔

Clinical trial diversity

As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.

By PharmaVoice staff

Harnessing the creative energy of California, Alto is advancing a novel approach to psychiatric meds

After making the leap from academia to the world of biotech, CEO Dr. Amit Etkin is hoping to shift the treatment paradigm for neurological conditions.

By Alexandra Pecci • Oct. 11, 2022

New partnership may give MDMA an edge in the psychedelics space

While LSD and psilocybin steal the spotlight, drug developers are also exploring MDMA for a wide swath of neurological illnesses. 

By Kelly Bilodeau • Oct. 10, 2022

The digital therapeutics revolution is happening and Big Pharma is buying in — with caution

Companies like Pfizer, Novartis, Sanofi and BMS are diving into the world of digital therapeutics while recognizing the limitations of the young field.

By Michael Gibney • Oct. 10, 2022

Woman of the Week: Janssen’s Fiona Elwood

The neurodegeneration lead at Janssen is driving precision-based medicine to better understand the pathology of neurological disease for the greatest patient impact.

By Taren Grom • Oct. 5, 2022

To stay on the leading edge of oncology, AbbVie knows it has to take risks

In a field that has seen rapid progress but ongoing areas of unmet need, AbbVie is betting on emerging tech.

By Kelly Bilodeau • Oct. 4, 2022

The 2 areas in life sciences most in need of talent

The industry is feeling the hiring crunch — here’s what pharma companies can do to mitigate the impact.

By Meagan Parrish • Oct. 4, 2022

It’s electric — speeding up the cell therapy process for scalability

To improve the development of cell therapy-based treatments, many companies are turning to a technology that uses electric fields.

By Alexandra Pecci • Oct. 4, 2022

Keytruda is the gift that keeps on giving for Merck, and here’s what’s next for the cancer juggernaut

Long-term results showed five-year survival numbers for lung cancer patients that surpassed all others, and Merck's VP of oncology research tells us what he's excited about.

By Michael Gibney • Oct. 3, 2022

Clinical trials haven’t harnessed the digital revolution — TransCelerate’s latest initiative aims to change that

The nonprofit’s VP of portfolio management discussed its “most transformative” digital initiative to date.

By PharmaVoice staff • Oct. 3, 2022

How do Biogen-Eisai’s two Alzheimer’s drugs stack up?

Biogen and Eisai's newest Alzheimer's success begs comparison to their past debacle — and bolsters the amyloid theory.

By Michael Gibney • Sept. 30, 2022

Woman of the Week: Pepper Bio’s Samantha Dale Strasser

The co-founder of Pepper Bio entered the biotech world three years ago with the goal of transforming drug discovery through the emerging discipline of transomics.

By Taren Grom • Sept. 28, 2022

Compass has the most advanced psychedelic drug in trials — but it needs a new approach to rollout to make it a success

The company's CEO, Kabir Nath, discusses potential roadblocks to commecialization that await its psilocybin treatment for depression. 

By Meagan Parrish • Sept. 27, 2022

Why precision medicine could be the next frontier in treating autism

Swiss-based Stalicla is banking on an AI-driven precision medicine discovery platform to deliver needed therapies in the autism space.

By Kelly Bilodeau • Sept. 27, 2022

Methadone at home? Emerging tech provides new tool in the fight against opioid addiction

Sonara Health’s inexpensive, specially engineered label and web app allow for at-home, digitally supervised dosing of high-cost or high-risks drugs.

By Alexandra Pecci • Sept. 15, 2022

Woman of the Week: Agilent Technologies’ Dr. Katharine Knobil

As the first chief medical officer of the diagnostic testing company, Dr. Katharine Knobil is focused on moving the science forward beyond precision oncology to liquid biopsy.

By Taren Grom • Sept. 14, 2022

Feds could soon bring COVID-style fight to superbug threat

COVID-19 has inspired renewed urgency in the need for weapons to combat antimicrobial resistant infections and new hope of government funding to meet the challenge.

By Karissa Waddick • Sept. 13, 2022

Clinical registry data, a valuable source of real-world data

Real-world data (RWD) from clinical drug registries can and should be used throughout the drug development lifecycle. At all stages, registries ensure that assumptions about the current standard of care are accurate and evidence-based.

By CorEvitas • Sept. 6, 2022

Pharma’s renewed sickle cell investment lifts a once-shirked disease

Pfizer's $5.4 billion deal to acquire Global Blood Therapeutics invigorated the fast-growing market, and patients are fit to be the benefactors.

By Kelly Bilodeau • Sept. 1, 2022

Woman of the Week: Thread’s Kim Boericke

Fresh off an eight-year tour of duty at ICON, the CRO industry veteran is stepping into a new role and a new title as chief delivery officer at Thread.

By Taren Grom • Aug. 31, 2022

Moderna’s lawsuit against Pfizer and BioNTech explained in 10 quotes

The biotech says that its competitors’ COVID-19 vaccine copied proprietary mRNA technology. Here’s a breakdown of the case.

By Karissa Waddick • Aug. 31, 2022

Parexel joins pharmacy giants in quest to boost community health clinical trials

The Community Alliance Network is the latest industry initiative looking to the pharmacy counter to help improve trial recruitment diversity.

By Taren Grom and Karissa Waddick • Aug. 30, 2022

Leading the industry’s next potential game-changer in drug discovery

Rachel Meyers, chief scientific officer at Faze Medicines, is helping guide the company towards the development of biomolecular condensates — an emerging field that could transform drug discovery.

By Alexandra Pecci • Aug. 29, 2022

The ‘long COVID’ nightmare: Data-driven alliance offers understanding of the lasting viral impact

A collaboration between Stanford University researchers and Komodo Health aims to advance knowledge of lingering COVID symptoms, health disparities and intervention strategies.

By Michael Gibney • Aug. 29, 2022